R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
cancer cells and Enhance Efficacy
NTX-101
- HOME
- R&D
- NTX-101
Eye Drops for Glaucoma
NTX-101 is the first-in-class eye drops that inhibit the activity of the well-established target 11β-HSD1
by simultaneously lowering intraocular pressure and protecting the optic nerve.
NTX-101 is being developed as a therapy for glaucoma.
NTX-101 Mechanism of Action
Inhibition of the cortisol concentrator 11β-HSD1 confers direct optic nerve protection
Clinical trial status
Project | Indication | Development Stage Discovery
Preclinical
Phase 1
Phase 2
Phase 3
|
Clinical Site |
---|---|---|---|
NTX-101 | Glaucoma | - KR Phase 1(finished) |